developing some focused you and our delivering. start of good On a brief morning XXXX year today's on investor excited therapies of be pleasure and It's that our underserved is XXXX review with over call. We're our past full and QX accomplishments novel remain execution, Thank and the a Abeona I'll call, cell for for to patient year today gene populations our community. you, Greg, again my year to we and key with of execution bullosa, start by talk and we the to caused pandemic, for dystrophic very treatments XXXX. advance as continue lead patients and program, call types In our refer to as programs Despite IIIA MPS proud to as three respectively. macro syndrome with referred our Sanfilippo to recessive you RDEB I'll the urgent epidermolysis of on I'm the MPS to as disruptions team. and bringing IIIB, clinical about 'XX, fast well B, as A our needed 'XX all I'll
up let's start XXXX. with remember Phase to X/X July X in overview of Stanford in center. associated world at at for the treatment First, of at the treatment EB-XXX resulted Pediatric in VIITAL brief wounds In five and healing EB-XXX 'XX, we Earlier presented in for program, our with as pivotal of our pain patients, relief large we improvement initiated our a year, a Society RDEB data chronic showing renowned look for University, Phase the for EB wound you'll long-term also pivotal and substantial and durable EB-XXX years. study lead Dermatology
months us data they wounds, problematic are ultimately proof-of-concept lead was age. up like years from for characterized of to some the severe Phase large longer for recurrent wounds plus centimeters patients and wounds greater, no at chronic can the wounds EB start dressing for heal RDEB. with longer wounds; trial most our This These in XX pivotal unfortunately, to as centimeter as or our and also lead change, Stanford are and of to serves use, VIITAL wounds significant hours namely XXX most They study. RDEB. University, XX themselves validating suffering as that reminder, demise day a or it generated XX more busy opioid going most centimeters, X/X pain, patients six to and and by exciting As issues, XXX blistering and per open
patients late three we or met in positive. XXXX, the Next, we with after with formal VIITAL two summer, was recurring December in The the result B meeting of a meeting in Type reported, previously FDA. very of as the
the resulted shared endpoints co-primary pivotal the for Our with in VIITAL FDA on interaction trial. alignment
FDA than determined RDEB wound advance wounds treated As us believe these are very with for wounds with using month X scores by endpoints. mean pivotal difference untreated closer reminder, thank wound treated and the meaningful pain are, partnership validated change second at dressing or FACES or also baseline month study And very endpoints VIITAL week assessment. co-primary investigator and the And scale clarity clinically We week comparing a greater the was X, untreated and a forward direct XX% important from patients. assessed endpoint the This healing helping sites the one X. we of their associated and wound the in the XX Wong-Baker step at proportion with comparing Phase step and XX reduction FDA. by to appropriate
excited in FDA to upon February. know biopsied study you identified, the the was protocol fourth treated VIITAL I'm and in immediately Next, with amendment alignment in let January patient the and XX, that very
for ongoing report week, surgical this is their at priority Stanford we we and enrollment five April. XXXX, in biopsied and pleased patient remains that as Abeona earlier at transplantation our anticipate very top are was mid addition, to In
to with top accrual Finally, patient regard priority. our
eligibility for Additional potential participation. They're being identified. patients have determine been to prescreened their study
goals Overall, for of anywhere the screening for us and pivotal between meet XXXX. of hopefully to CX vaccines they genetic due KOL mutations, on has target as on recessive complete program. lead prescreening and Last number it an wounds is We on meet the very patients our news, community RDEB. our our criteria VIITAL start the very tests, accrual two XXXX. way exciting the are our with but total. chronic the against the way the reminder, across patients operational for to both accrual has EB meeting enrollment we patterns take we inherited a and focus recall our including focus being with to XX during is causing way the our more ensure key a of and even goal QX that confirmed in approximately XX interest and derived, momentum our slow difficult patient seems laser to their excellence most to increased not of importantly from Type trial, program treatment on to believe milestones B is battery to Stanford treated more but now from team's patients, pleased in a to The Please time, As are and pandemic to four progress of it the importantly, ED-XXX recent XX in world. patient treatment enrolled five large the hold
have large center on-boarding We currently in two. as we number medical a academic selected that ED site the northeast are
going I half release VIITAL, As IRB running their for have the hope name yet they second still because this want approval approval, I half and the to we and the the will to of them about year two of speaking to of not through make we are second just up as of reasons. before, but for finish be in we'll agreed stated site soon to sure you IRB Stanford, on out they Even VIITAL to we I've second that. a though through pace XXXX approval, main get are and
coast families. the our number offer east wanted We to an barrier listening and was easier XXXX on to participation in patients, First, due option study and travel for logistics traveling to patients the one where to some COVID. make
we EB-XXX positive of potentially goal with for United as is Second, the standard EB-XXX get results, care dystrophic bullosa HCP all commercializing EB-XXX as having patients closer necessary hopefully in experience XXXX, States. to expanding recessive epidermolysis as with in meeting our the in pending
of our turn as AAV-based my virus IIIA. program Now our Namely, therapy known from is therapy gene program standpoint adeno-associated other gene ABO-XXX, attention or our the first MPS portfolio to our I'll programs. AAV half
we as completed out the was and the corporate is times been in to dose enrollment quarter XXXX. As target our the laid FDA IIIA fourth study kilogram, in XX A Transpher milestones XX dose XX in about we the year. of vector have a patients per XX ABO-XXX the dosed XXXX for later reminder, To-date patients MPS for A in Transpher this goals safe the and X to higher believe the and be efficacious, including study, cohort that three, genomes speaking dose we'll in
study was it results leave for at patients A for for MPS third the lead We Transpher safety we'll the do our with enrollment, least meeting Two, to dose reasons. higher Type patient continue of the positive FDA also B open thing the communicated treatment efficacy we the afflicted lack call it based cohort, thought the options on received One, from two to on quarter right main open patients. to with that to and IIIA. through
XX addition, many late X.X children, last neurocognitive In Transpher are during were plus well as years to Why breaking were X was development at months, patients investor important? within Their were again of from very life-altering which platform potential MPS These later, respectively be X X.X has with months, range ABO-XXX month, age their treated the excited years The cohort A, at a latest years provide data updated the Transpher time this results, and hope MPS interim critical IIIA. from is XX IIIA to to at share patients non-afflicted just the to which treated. as continues point. plus ABO-XXX to into months with for we X.X they age and current families. presented children our ages of and a with The X webinar, data to a symposium, subsequent treatment preserved all session demonstrated as a for so continue the is post-treatment the option of X you that at and patients ranges that few to youngest three dose suggest days the reminder with XX now chronologically. world normal
disease of As we far neurocognitive usually approved natural declines IIIA about years without which history development today. by a none intervention, being X the see thus MPS therapeutic
We is the A with excited in NPS data To very meeting, marketing June. quite they're not our ABO-XXX. the from requested next are are in date We as you being in any viable this upcoming reminder, the appreciate companies, we're for arm. BLA dataset about believe children for has with have as met told all viable We're discuss these discuss to hoping with data a demented the in mid-XXXX, to A FDA submission, EMA Europe whether in We development be set steps this we of and data disease the review the forward. could it are we the been to history intend the them and a inundated feasible life authorization day, meeting path FDA FDA next and we as potential January control FDA by believe FDA. the prime COVID. data, backbone as at viable to with We and 'XX. important a science to is we excited with for give natural under pass a for follows. and most steps designation that the We placebo. with BLA a Also we this discuss serve for our a a plan as work with meeting a as Transpher
EMA refine steps our expect probably the second plans of later FDA our filter next development have interaction in pathway into in and further with the our We June to will we a half discussion year. with this them targeted to again and from
biomarkers third at is X data our here February in the the today 'XX onto higher MPS higher data and in B dosed in were Transpher B They follow-up XX interim fluid dose study. Moving XX heparan look show times associated with neurocognitive Transpher including for I'm this treatment need improvements A to standard assess The breaking world XXXX as urine CNS, at the known patients and gold dose a Transpher -- ABO-XXX's sustained systemic MPS cerebral cohort potential matures. XX. accepted old cohort. in later forward GAGs. symposium, B, continued to including sulfate patients to onward like in presentation dependent heparan XD reminder IIIB. sulfate and encouraging. into was clinic neurocognitive to results preserve late patients of here plasma and also updated new for also spinal dose and urine In four with year XX as was program a have and for been glycosaminoglycans ABO-XXX We assessment development, the sorry the
concluding of the you, stability be the with as patient we which with investment for Finally, Children's forward we in patients need. in Transpher will call. Hospital accrual We're product to our working we'll remind we QX being I'll Nationwide product. last community. the used update stated and the clinical you currently on next to is testing time B, prior After product our potentially treat on regard assess this on B, point not as the as in options investigators Transpher to the completion our We MPS community discussed clarity remaining have testing, and have as timelines soon patients plan after quarterly
CLNX of ABO-XXX as with 'XX, Gene material an to strategic the these syndrome. this Taysha patients non-core near-term turning certain gene partnerships partner therapy gene of opportunity will the knowhow entered gene AAV-based we value a Next, and share the two Most future in therapy and as needed for programs. in rights importantly, with earliest development highest this therapies expedite to stage disease for IP these to for unmet put need. relating the corporate and that milestones provided batten potential rights deals well of that for a overall organizational infantile asset into Therapies much to success disease in progress hands Abeona AAV-based provide transaction The or assets again in patient unlocked Rett
current members It was to governance experience, their morning, the of new on objectives of them Next, look creating next our corporate long-term Abeona, our my enhancing that growth, helping our path am two experiences partners experience both as additional in right to leadership to phase in forward further operational phase, I independent appointed and shareholder drive excited for oversight operational assisting relevant Abeona, very Board our of board our and excellence on members want leadership, strengthening team and to in in science. based for we the future our for Directors, value. to selection. this these making I specifically their comment management near-and announce diverse life us add we operational
our us anticipate we X let's the in you a fingers Milestone past to of enrollment XXXX over ABO-XXX, a anticipated meeting as The and the reminder that IIIA accomplishments in review our we June move assuring put as of COVID expect fast on forward MPS be for across. VIITAL to available to the the year milestones QX and 'XX. into we check expectation data XXXX execution will study give Finally, immediately BLA objective, very key already track XXXX box first line the a will what continue Type the from positive current completing our have in our B as FDA and focused us. mid related our study, filing clinics with in followed in enrollment see plan path discuss can program for Number in to positive assuming complete will two a patients. in be can the for EB-XXX one, by phase VIITAL Based more and programs 'XX, you assuming closer XXXX, my on results. which pivotal we no me patient be delays momentum top in regarding
Bircher's a In leadership Ohio. I ops under addition, of in we grade year, believe the first ABO-XXX Abeona tech lot is the group lifeblood group this and second for our of produced Jay of expect to organization. in milestone half our exciting we say this released be very Cleveland, the our product clinical often for
X, X. of the been as and first have X, and in this and we patients patients, follow-up younger X, both the patients, neurocognitive year, visits patients, cohort as treated additional the well three Finally, assessments later expect who
the As to an very year three of to a point will cohort dosed X, disease that two X the be have patients in patients. natural time these up neurocognitive history assessment And can patient. is compare progression we we the in of where because a year the untreated reminder significant past time point chronologically
in know you in more will plan, Number we're IIIB. dissemination on clear MPS when exactly three, let Congress program, exact last our regarding ABO-XXX will data We clinic what our about target.
to program will plans IIIA continue the as stability will patients the MPS we'll June IIIB. as MPS in to filter we all and FDA's work it's Once our the DMA stability guide will for note receive IIIA testing into will from clinical of completion will for for points tests, learning treating our remaining a and be from Transpher feedback our for for through significant four timely IIIB plans nationwide. We have we weeks the Also, important B. well time for both options MPS past programs product product that that absolutely assess immediately
expect can Transpher when and some from occur. updates we that Finally, year, later are additional dissemination designated data congresses this data we early and B will you let our clinical know see to will data, as neurocognitive
now prioritization Let's rich our focusing prioritize preclinical briefly work in and we our review. indications begin strategic a to new to ophthalmic our from following started shift pipeline. adding to resources have on We're clinic programs
the our programs some and we're the MPS in-house and and IIIB, of conducting On partner assessing back six disorders. eye our research undisclosed of preclinical progress AAV from capture AAV IIIA in
toward We to to XX. IND in two indications studies two enabling three six. of We'll pick are in three the executing
these make very, XX,XXX alone now U.S. in spaces, Each Just right paths as are of sure you to more are indications concrete want idea very to the about an indications these patients. give to undisclosed we and represents busy the forward. while have X I
in AAV markets to we're programs bigger some patient starting So, our need. parlay to success tremendous with
I thank in studies meetings I and the us this QX Q&A. non-human I'm a so you or for from Ultimately, conversation results before forward Accounting it have Ed, in over turn Carr, please look time into my studies substantive lead in guide studies financial have will it 'XX. XXXX. into these our Officer, examine And primate today. you full toxicology away. results. through going to HX And to the hand, plan these to and take we proof-of-concept some could he year. QX, pre-IND to take expect We right us Ed your results to that, them of Chief year
